Why Current Legislative Efforts to Prevent Patent Thickets Are a Start — But Not EnoughTo prevent patent thickets, we have to do more than trim around the hedges. We have to stop patent thickets from taking root.Apr 3, 2024Apr 3, 2024
America’s Drug Pricing Problem Needs a New DiagnosisFar too many Americans are unable to afford their medicationMar 21, 2024Mar 21, 2024
Think “Squid Game” is Scary? Our Real Life Vaccine Inequity is WorseSquid Game feels more like a reality show chronicling our current vaccine inequity than a terrifying fantasy.Oct 28, 2021Oct 28, 2021
The quest for a Covid-19 vaccine cannot be infected by profit motivesIn the early-to-mid 2000s, as concerns were growing about an avian flu outbreak, governments began stockpiling Tamiflu. The buying frenzy…Nov 23, 2020Nov 23, 2020
Celgene didn’t invent Revlimid. But it has made billions from overpatentingYesterday, the former CEO of the pharmaceutical company Celgene appeared before the House Committee on Oversight and Reform to explain the…Oct 1, 2020Oct 1, 2020
The never-ending drip of pharmaceutical patentsAs expectations for a COVID-19 vaccine grow, so too have concerns about access among the public and even politicians. Democratic…Aug 18, 2020Aug 18, 2020
The Reality of Pharmaceutical Profits and Public HealthIn their recent piece, “Pharmaceutical Profits and Public Health Are Not Incompatible,” Daniel Hemel and Lisa Larrimore Ouellette argue…Jun 15, 2020Jun 15, 2020